{"preliminary_commentary":{"by_channel":{"podcast":26,"x_thread":25,"youtube":20},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03897881\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"KEYNOTE-942","nct_id":"NCT03897881","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=keynote-942-nct03897881. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Participants will receive up to 9 doses of mRNA-4157 (every 21 days). Participants may continue on pembrolizumab (every 21 days) until disease recurrence, unacceptable toxicity, or they undergo up to 18 total cycles (approximately 1 year of treatment), whichever is sooner.","label":"mRNA-4157 and Pembrolizumab","type":"EXPERIMENTAL"},{"description":"Participants will receive pembrolizumab (every 21 days) until disease recurrence, unacceptable toxicity, or they undergo up to 18 total cycles (approximately 1 year of treatment), whichever is sooner.","label":"Pembrolizumab","type":"ACTIVE_COMPARATOR"}],"collaborators":["Merck Sharp & Dohme LLC"],"completion_date":{"date":"2032-11-21","type":"ESTIMATED"},"conditions":["Melanoma"],"enrollment":{"count":267,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"mRNA-4157","otherNames":[],"type":"DRUG"},{"name":"Pembrolizumab","otherNames":[],"type":"BIOLOGICAL"}],"last_update":"2026-09-08","lead_sponsor":"ModernaTX, Inc.","official_title":"A Phase 2 Randomized Study of Adjuvant Immunotherapy With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab Versus Pembrolizumab Alone After Complete Resection of High-Risk Melanoma (KEYNOTE- 942)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2032-11-21","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Recurrence-Free Survival (RFS), Assessed Using Radiological Imaging","timeFrame":"Up to 7 years"}],"references":[{"citation":"Khattak A, Carlino MS, Meniawy T, Ansstas G, Taylor MH, Kim KB, McKean M, Long GV, Sullivan RJ, Faries M, Tran TT, Cowey CL, Pecora A, Medina T, Atkinson V, Krepler C, Jemielita T, Mao H, Chow J, Ojalvo LS, Mehnert JM; KEYNOTE-942 Investigators. Intismeran Autogene Plus Pembrolizumab Versus Pembrolizumab Alone in High-Risk Resected Melanoma: 5-Year Update of the Randomized Phase IIb KEYNOTE-942 Study. J Clin Oncol. 2026 Jun 1:JCO2600835. doi: 10.1200/JCO-26-00835. Online ahead of print.","pmid":"42223134","type":"DERIVED"},{"citation":"Weber JS, Carlino MS, Khattak A, Meniawy T, Ansstas G, Taylor MH, Kim KB, McKean M, Long GV, Sullivan RJ, Faries M, Tran TT, Cowey CL, Pecora A, Shaheen M, Segar J, Medina T, Atkinson V, Gibney GT, Luke JJ, Thomas S, Buchbinder EI, Healy JA, Huang M, Morrissey M, Feldman I, Sehgal V, Robert-Tissot C, Hou P, Zhu L, Brown M, Aanur P, Meehan RS, Zaks T. Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study. Lancet. 2024 Feb 17;403(10427):632-644. doi: 10.1016/S0140-6736(23)02268-7. Epub 2024 Jan 18.","pmid":"38246194","type":"DERIVED"}],"start_date":{"date":"2019-07-18","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942)","url":"https://clinicaltrials.gov/study/NCT03897881"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/keynote-942-nct03897881"}